Evogene (EVGN) Operating Expenses (2012 - 2026)

Over the twelve months ended Jun 30, 2026, Evogene's Operating Expenses came in at $12.18 million, down 31.6% year-over-year; for the year ended Dec 31, 2025, it came in at $11.44 million, down 48.0% from the prior year.

• Operating Expenses has declined for four consecutive years, with a five-year compound annual growth rate of -14.7% (years ended Dec 2020 to Dec 2025).
• By year, Operating Expenses came in at $22 million in the year ended Dec 31, 2024 (-7.3%), $23.72 million in the year ended Dec 31, 2023 (-14.4%), $27.71 million in the year ended Dec 31, 2022 (-11.0%) and $31.12 million in the year ended Dec 31, 2021 (+23.1%).
• The figure for the quarter ended Jun 30, 2026 ranks as the lowest quarterly Operating Expenses in data going back to the quarter ended Dec 31, 2012.
• Year over year, Operating Expenses has now declined in each of the last nine quarters, with an average decline of 31.3% over the last eight quarters.
• The high point for year-over-year Operating Expenses in five years was the quarter ended Dec 31, 2023 (growth of 91.5%); the low point was the quarter ended Sep 30, 2025 (a decline of 56.5%).
• Per Business Quant data, the three quarters before the quarter ended Jun 30, 2026 came in at $3.35 million (quarter ended Mar 31, 2026), $3.24 million (quarter ended Dec 31, 2025) and $2.88 million (quarter ended Sep 30, 2025).